In one of the largest qui tam False Claims Act (“FCA”) settlements of 2017, pharmaceutical company Mylan Inc. entered into a $465 million dollar settlement.  Our Los Angeles based qui tam FCA whistleblower attorneys reported that the allegations stemmed from allegations that Mylan violated the FCA by misclassifyin...